ADA 2026

Real-World Evaluation of a Personalized, Multilingual Digital Diabetes Care Model across Metropolitan and Nonmetropolitan India

by Prateek Chopra | June 27, 2026 | Diabetes Conferences | ADA 2026 Program Overview Program Features Methods Study Population Engagement Patterns Clinical Outcomes Age-Stratified Findings Clinical Implications The Sugar.fit multilingual digital diabetes program achieved high engagement and clinically meaningful improvements in glycemic control and weight across both metropolitan and nonmetropolitan populations. These findings support the scalability and equity of

Real-World Evaluation of a Personalized, Multilingual Digital Diabetes Care Model across Metropolitan and Nonmetropolitan India Read Post »

Leave a Comment / Diabetes Conferences / / / , , , ,

Disparities in Sodium–Glucose Cotransporter Inhibitor Use: A Systematic Literature Review

by Prateek Chopra | June 27, 2026 | Diabetes Conferences | ADA 2026 Clinical Objective Methods Study Selection Key Findings Potential Contributors to Disparities Clinical Implications Evidence from this systematic review indicates persistent sociodemographic disparities in SGLT2 inhibitor utilization across the United States. Further research is needed to better understand the drivers of these inequities and develop strategies to improve

Disparities in Sodium–Glucose Cotransporter Inhibitor Use: A Systematic Literature Review Read Post »

Leave a Comment / Diabetes Conferences / / / , , , , ,

Efficacy and Safety of Simplified SGLT2i-Based Stepwise Intensive Therapy in Inducing Diabetes Remission in Newly Diagnosed Type 2 Diabetes with Severe Hyperglycemia: A Pilot Study

by Prateek Chopra | June 26, 2026 | Diabetes Conferences | ADA 2026 Study Objective Methods Primary Endpoint Study Population Remission Outcomes Metabolic Outcomes Safety SGLT2i-based stepwise intensive therapy achieved remission rates comparable to conventional SIT while providing greater improvements in insulin sensitivity and BMI. This simplified outpatient-oriented approach may offer a practical alternative to prolonged inpatient intensive insulin therapy

Efficacy and Safety of Simplified SGLT2i-Based Stepwise Intensive Therapy in Inducing Diabetes Remission in Newly Diagnosed Type 2 Diabetes with Severe Hyperglycemia: A Pilot Study Read Post »

Leave a Comment / Diabetes Conferences / / / , , , ,

Effects of Empagliflozin on Hepatic Glucose Production, Gluconeogenesis, and Lipolysis in Type 2 Diabetes

by Prateek Chopra | June 26, 2026 | Diabetes Conferences | ADA 2026 Study Objective Methods Effects on Hepatic Glucose Metabolism Effects on Lipolysis Mechanistic Insights Clinical Implications Empagliflozin increased both gluconeogenesis and lipolysis in individuals with type 2 diabetes, with glycerol acting as an important gluconeogenic substrate. These compensatory metabolic responses help preserve hepatic glucose production and may explain

Effects of Empagliflozin on Hepatic Glucose Production, Gluconeogenesis, and Lipolysis in Type 2 Diabetes Read Post »

Leave a Comment / Diabetes Conferences / / / , , , , ,

The Natural History of Type 2 Diabetes Varies Between Clinical Subphenotypes of At-Risk Individuals

by Prateek Chopra | June 25, 2026 | Diabetes Conferences | ADA 2026 Research Objective Methods High-Risk Metabolic Clusters Study Population Changes in Insulin Sensitivity Changes in Beta-Cell Function Adiposity Trajectories Clinical Implications High-risk metabolic subphenotypes follow different pathways toward the development of T2D. While progressive insulin resistance predominates in some individuals, accelerated beta-cell deterioration drives diabetes onset in others,

The Natural History of Type 2 Diabetes Varies Between Clinical Subphenotypes of At-Risk Individuals Read Post »

Leave a Comment / Diabetes Conferences / / / , , , , ,

CGM for Adults with Type 2 Diabetes Not on Insulin Therapy: The CONNECT Randomized Controlled Trial

by Prateek Chopra | June 24, 2026 | Diabetes Conferences | ADA 2026 Study Objective Trial Design Study Assessments Baseline Characteristics Baseline Medication Use Clinical Implications Baseline findings from the CONNECT trial highlight persistent gaps in glycemic management among adults with non-insulin-treated T2D. The ongoing study will determine whether CGM can improve glycemic outcomes and support more effective diabetes management

CGM for Adults with Type 2 Diabetes Not on Insulin Therapy: The CONNECT Randomized Controlled Trial Read Post »

Leave a Comment / Diabetes Conferences / / / , , , , ,

Prescribing Trends and Comparative Risk of Type 2 Diabetes Progression in Prediabetes by Antihyperglycemic Drug Class

by Prateek Chopra | June 24, 2026 | Diabetes Conferences | ADA 2026 Need for Diabetes Prevention Methods Primary Outcome Risk of Progression to Type 2 Diabetes Clinical Implications In this large real-world analysis, GLP-1RAs, GIP/GLP-1RAs, and SGLT2 inhibitors were associated with significantly lower rates of incident T2D compared with metformin. Among these therapies, GIP/GLP-1RAs provided the greatest protection against

Prescribing Trends and Comparative Risk of Type 2 Diabetes Progression in Prediabetes by Antihyperglycemic Drug Class Read Post »

Leave a Comment / Diabetes Conferences / / / , , , , ,

ABC Transporters as Surrogate Biomarkers of HDL Functionality for EarlyAtherosclerosis Risk Assessment in Type 2 Diabetes Mellitus

by Prateek Chopra | June 24, 2026 | Diabetes Conferences | ADA 2026 Clinical Significance Study Population Methods ABC Transporter Levels and HDL Functionality Impact on HDL Functionality Discriminatory Performance Clinical Implications Individuals with T2DM, particularly those with atherosclerosis, exhibited impaired HDL functionality despite similar HDL-C levels. Lower circulating ABCA1 and ABCG1 levels were associated with reduced cholesterol efflux capacity,

ABC Transporters as Surrogate Biomarkers of HDL Functionality for EarlyAtherosclerosis Risk Assessment in Type 2 Diabetes Mellitus Read Post »

Leave a Comment / Diabetes Conferences / / / , , , , ,

The Cardioprotective Effect of Glucagon-Like Peptide 1 Receptor Agonist ina Trial Inspired, And Wider, Population Individuals Living with Type 2Diabetes: A Target Trial Emulation Study in CPRD

by Prateek Chopra | June 23, 2026 | Diabetes Conferences | ADA 2026 Clinical Context Methods Study Population Cardiovascular Outcomes in the Trial-Matched Cohort Cardiovascular Outcomes in the Non-Trial Cohort Clinical Implications GLP-1RA therapy was associated with a lower risk of major adverse cardiovascular events among individuals meeting LEADER trial eligibility criteria but not among those outside the trial population.

The Cardioprotective Effect of Glucagon-Like Peptide 1 Receptor Agonist ina Trial Inspired, And Wider, Population Individuals Living with Type 2Diabetes: A Target Trial Emulation Study in CPRD Read Post »

Leave a Comment / Diabetes Conferences / / / , , , , , ,

A1C and BMI Changes by Sociodemographic Groups Among Patients UsingGLP-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors(SGLT-2i) in a Large Integrated Health System

by Prateek Chopra | June 23, 2026 | Diabetes Conferences | ADA 2026 | 0 comments Clinical Relevance Methods Study Population Glycemic and Weight Outcomes Differences Across Demographic Groups Clinical Implications In a real-world healthcare setting, GLP-1 RA therapy was associated with clinically meaningful reductions in HbA1c and BMI among patients with T2DM and obesity. Greater benefits observed in specific racial, ethnic,

A1C and BMI Changes by Sociodemographic Groups Among Patients UsingGLP-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors(SGLT-2i) in a Large Integrated Health System Read Post »

Leave a Comment / Diabetes Conferences / / / , , , , ,
Scroll to Top